(Albany, USA) DelveInsight’s “Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Hypoparathyroidism market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Hypoparathyroidism market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Hypoparathyroidism treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Hypoparathyroidism market.
Request for a Free Sample Report @ Hypoparathyroidism Market Forecast
Some facts of the Hypoparathyroidism Market Report are:
· According to DelveInsight, Hypoparathyroidism market size is expected to grow at a decent CAGR by 2032.
· Leading Hypoparathyroidism companies working in the market are Ascendis Pharma, Amolyt Pharma, Bridgebio, Calcilytix Therapeutics, Aerami Therapeutics Inc, Aeterna Zentaris Inc, BridgeBio Pharma Inc, Eli Lilly, Entera Bio Ltd, Extend Biosciences, GC Biopharma Corp, MBX Biosciences Inc, ProLynx, Rani Therapeutics and others.
· Key Hypoparathyroidism Therapies expected to launch in the market are TRANSCON PTH (palopegteriparatide), Eneboparatide (AZP-3601), Encaleret (BBP-305/CLTX-305), and many others.
· On March 2024, Amolyt Pharma announced results of a Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Eneboparatide (AZP-3601), a Parathyroid Hormone Receptor Agonist, in Patients With Chronic Hypoparathyroidism (CALYPSO)
· On January 2024, Ascendis Pharma A/S announced results of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism: PaTHway TRIAL.
· On November 2023, Entera Bio Ltd announced results of a Phase 1b, Open-label, Partially Randomised Study to Assess Safety and Compare Pharmacokinetics of New Oral hPTH(1-34) Tablet Formulations vs. Oral EBP05 Tablets and Subcutaneous Forteo® Injection in Healthy Male Subjects.
· On May 2022, Visen Pharmaceuticals (Shanghai) Co., Ltd. announced results of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism: PaTHway CHINA TRIAL
Hypoparathyroidism Overview
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production or action of parathyroid hormone (PTH), leading to low levels of calcium in the blood and high levels of phosphate. This imbalance disrupts the body’s calcium regulation, causing symptoms such as muscle cramps, tingling sensations, seizures, and mood disturbances. The most common cause is damage to or removal of the parathyroid glands during thyroid surgery, although autoimmune conditions and genetic factors can also contribute. Diagnosis typically involves blood tests to measure calcium, phosphate, and PTH levels. Treatment aims to restore calcium balance and prevent complications. This often involves supplementation with calcium and active vitamin D analogs to increase calcium absorption from the gut and reduce phosphate levels. Regular monitoring of calcium and vitamin D levels is essential to adjust treatment and prevent complications such as kidney stones, osteoporosis, and calcifications in the brain. Despite available treatments, managing hypoparathyroidism can be challenging, requiring ongoing medical care and support to maintain optimal calcium levels and quality of life.
Do you know what will be the Hypoparathyroidism market share in 7MM by 2032 @ https://www.delveinsight.com/sample-request/hypoparathyroidism-market
Hypoparathyroidism Market
The Hypoparathyroidism market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Hypoparathyroidism market trends by analyzing the impact of current Hypoparathyroidism therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Hypoparathyroidism market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hypoparathyroidism market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Hypoparathyroidism market in 7MM is expected to witness a major change in the study period 2019-2032.
Hypoparathyroidism Epidemiology
The Hypoparathyroidism epidemiology section provides insights into the historical and current Hypoparathyroidism patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Hypoparathyroidism market report also provides the diagnosed patient pool, trends, and assumptions.
Interested to know how the emerging diagnostic approaches will be contributing in increased Hypoparathyroidism diagnosed prevalence pool? Download report @ https://www.delveinsight.com/sample-request/hypoparathyroidism-market
Hypoparathyroidism Drugs Uptake
This section focuses on the uptake rate of the potential Hypoparathyroidism drugs recently launched in the Hypoparathyroidism market or expected to be launched in 2019-2032. The analysis covers the Hypoparathyroidism market uptake by drugs, patient uptake by therapies, and sales of each drug.
Hypoparathyroidism Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Hypoparathyroidism market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Hypoparathyroidism Pipeline Development Activities
The Hypoparathyroidism report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Hypoparathyroidism key players involved in developing targeted therapeutics.
Download report to know which TOP 3 therapies will be capturing the largest Hypoparathyroidism market share by 2032? Click here @ https://www.delveinsight.com/sample-request/hypoparathyroidism-market
Hypoparathyroidism Therapeutics Assessment
Major key companies are working proactively in the Hypoparathyroidism Therapeutics market to develop novel therapies which will drive the Hypoparathyroidism treatment markets in the upcoming years are Ascendis Pharma, Amolyt Pharma, Bridgebio, Calcilytix Therapeutics, Aerami Therapeutics Inc, Aeterna Zentaris Inc, BridgeBio Pharma Inc, Eli Lilly, Entera Bio Ltd, Extend Biosciences, GC Biopharma Corp, MBX Biosciences Inc, ProLynx, Rani Therapeutics and others.
Do you know how TRANSCON PTH and Eneboparatide market launch will be impacting the Hypoparathyroidism market CAGR? Download sample report @ https://www.delveinsight.com/sample-request/hypoparathyroidism-market
Hypoparathyroidism Report Key Insights
1. Hypoparathyroidism Patient Population
2. Hypoparathyroidism Market Size and Trends
3. Key Cross Competition in the Hypoparathyroidism Market
4. Hypoparathyroidism Market Dynamics (Key Drivers and Barriers)
5. Hypoparathyroidism Market Opportunities
6. Hypoparathyroidism Therapeutic Approaches
7. Hypoparathyroidism Pipeline Analysis
8. Hypoparathyroidism Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Hypoparathyroidism Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Hypoparathyroidism Competitive Intelligence Analysis
4. Hypoparathyroidism Market Overview at a Glance
5. Hypoparathyroidism Disease Background and Overview
6. Hypoparathyroidism Patient Journey
7. Hypoparathyroidism Epidemiology and Patient Population
8. Hypoparathyroidism Treatment Algorithm, Current Treatment, and Medical Practices
9. Hypoparathyroidism Unmet Needs
10. Key Endpoints of Hypoparathyroidism Treatment
11. Hypoparathyroidism Marketed Products
12. Hypoparathyroidism Emerging Therapies
13. Hypoparathyroidism Seven Major Market Analysis
14. Attribute Analysis
15. Hypoparathyroidism Market Outlook (7 major markets)
16. Hypoparathyroidism Access and Reimbursement Overview
17. KOL Views on the Hypoparathyroidism Market
18. Hypoparathyroidism Market Drivers
19. Hypoparathyroidism Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Hypoparathyroidism Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight | TRANSCON PTH (palopegteriparatide), Eneboparatide (AZP-3601), Encaleret (BBP-305/CLTX-305), more
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services